Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25904153 | 0.84 | ALOX15 (0.48) | ALOX15CYP2D6CYP1A2OPRL1KCNH2 | |
| SCHEMBL25924571 | 0.72 | CXCR3 (0.43) | ALOX15 | |
| SCHEMBL29324717 | 0.70 | CYP1A2 (0.42) | ALOX15CYP2D6CYP1A2OPRL1KCNH2 | |
| SCHEMBL26138785 | 0.69 | CXCR3 (0.49) | CYP2D6KCNH2HRH3HSD11B1 | |
| SCHEMBL25856192 | 0.68 | CYP1A2 (0.41) | ALOX15CYP2D6CYP1A2OPRL1 | |
| SCHEMBL21934664 | 0.67 | CYP1A2 (0.36) | ALOX15CYP2D6CYP1A2OPRL1KCNH2 | |
| SCHEMBL17281941 | 0.67 | EPHX2 (0.51) | CYP2D6KCNH2HRH3HSD11B1 | |
| SCHEMBL25594298 | 0.67 | CYP2D6 (0.43) | CYP2D6CYP1A2 | |
| SCHEMBL29317714 | 0.66 | CYP2D6 (0.44) | ALOX15CYP2D6CYP1A2KCNH2HRH3 | |
| SCHEMBL12166744 | 0.66 | ACHE (0.47) | OPRL1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | ALOX15 2547/4885CYP2D6 2818/4885CYP1A2 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.